MDM4: What do we know about the association between its polymorphisms and cancer?

被引:0
|
作者
Gabriela Mattevi Almeida
Ana Clara Castilho
Douglas Adamoski
Karin Braun-Prado
机构
[1] Federal University of Parana,Post
[2] Brazilian Biosciences National Laboratory (LNBio),Graduation Program in Genetics, Department of Genetics
来源
关键词
MDMX; HDMX; SNP; Haplotype; Tumor;
D O I
暂无
中图分类号
学科分类号
摘要
MDM4 is an important p53-negative regulator, consequently, it is involved in cell proliferation, DNA repair, and apoptosis regulation. MDM4 overexpression and amplification are described to lead to cancer formation, metastasis, and poor disease prognosis. Several MDM4 SNPs are in non-coding regions, and some affect the MDM4 regulation by disrupting the micro RNA binding site in 3'UTR (untranslated region). Here, we gathered several association studies with different MDM4 SNPs and populations to understand the relationship between its SNPs and solid tumor risk. Many studies failed to replicate their results regarding different populations, cancer types, and risk genotypes, leading to conflicting conclusions. We suggested that distinct haplotype patterns in different populations might affect the association between MDM4 SNPs and cancer risk. Thus, we propose to investigate some linkage SNPs in specific haplotypes to provide informative MDM4 markers for association studies with cancer.
引用
收藏
相关论文
共 50 条
  • [1] MDM4: What do we know about the association between its polymorphisms and cancer?
    Almeida, Gabriela Mattevi
    Castilho, Ana Clara
    Adamoski, Douglas
    Braun-Prado, Karin
    MEDICAL ONCOLOGY, 2022, 40 (01)
  • [2] The associations between MDM4 gene polymorphisms and cancer risk
    Wang, Ming-Jie
    Luo, Yong-Jun
    Shi, Zhi-Yong
    Xu, Xiao-Liang
    Yao, Guo-Liang
    Liu, Rui-Ping
    Zhao, Hui
    ONCOTARGET, 2016, 7 (34) : 55611 - 55623
  • [3] WHAT DO WE KNOW ABOUT CANCER
    不详
    UMSCHAU IN WISSENSCHAFT UND TECHNIK, 1977, 77 (02) : 57 - 58
  • [4] What do we know and what do we know about evolution?
    Vlchev, Boris
    SPISANIE NA B LGARSKOTO GEOLOGICHESKO DRUZHESTOV-REVIEW OF THE BULGARIAN GEOLOGICAL SOCIETY, 2020, 81 : 101 - 101
  • [5] What do we know about the α/β for prostate cancer?
    Oliveira, S. M.
    Teixeira, N. J.
    Fernandes, L.
    MEDICAL PHYSICS, 2012, 39 (06) : 3189 - 3201
  • [6] What we know and what we do not know about DMN
    Figl, Kathrin
    Mendling, Jan
    Tokdemir, Gul
    Vanthienen, Jan
    ENTERPRISE MODELLING AND INFORMATION SYSTEMS ARCHITECTURES-AN INTERNATIONAL JOURNAL, 2018, 13
  • [7] Atrial fibrillation: what do we know about screening and what do we not know about treatment?
    Pokorney, Sean D.
    Lopes, Renato D.
    HEART, 2019, 105 (11) : 817 - 819
  • [8] H4+:: What do we know about it?
    Alijah, Alexander
    Varandas, Antonio J. C.
    JOURNAL OF CHEMICAL PHYSICS, 2008, 129 (03):
  • [9] WHAT DO WE KNOW ABOUT CANCER - BICENTENNIAL PERSPECTIVE
    SHIMKIN, MB
    WESTERN JOURNAL OF MEDICINE, 1976, 125 (06): : 509 - 512
  • [10] What do we really know about prostate cancer?
    Albertsen, Peter
    EUROPEAN UROLOGY, 2007, 52 (04) : 948 - 950